Australia's most trusted
source of pharma news
Posted 6 November 2024 PM
A patient who received Imugene's Vaxinia to treat bile tract cancer has maintained a complete response for more than two years, boosting the case for the immune stimulant.
Vaxinia, a genetically modified orthopoxvirus which can prime the immune system to be more responsive to immunotherapies, was given as a monotherapy or in combination with MSD's Keytruda in the Phase 1 MAST trial for patients with any metastatic or advanced solid tumor who have progressed after at least two prior lines of therapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.